瑞银发表报告，列出最具潜力超市场预期收益((Buy rated HK listed stocks with highest UBSe earnings upside above consensus estimate)的港股买入名单：股份│瑞银与同业对企业今明两年综合盈测差异康希诺生物(06185.HK) +1.020 (+2.401%) 沽空 $97.05万; 比率 2.608% │97%石药集团(01093.HK) -0.110 (-1.394%) 沽空 $2.74亿; 比率 11.356% │60%三生制药(01530.HK) +0.740 (+2.645%) 沽空 $5.29千万; 比率 10.707% │42%科济药业-B(02171.HK) +0.550 (+3.389%) 沽空 $5.72百万; 比率 37.642% │42%上石化(00338.HK) -0.010 (-0.730%) 沽空 $1.16百万; 比率 12.540% │37%越秀地产(00123.HK) +0.010 (+0.212%) 沽空 $4.13百万; 比率 24.856% │35%金风科技(02208.HK) -0.310 (-2.248%) 沽空 $1.59千万; 比率 3.143% │33%科伦博泰生物-B(06990.HK) -8.000 (-1.828%) 沽空 $1.81千万; 比率 6.318% │27%中信建投证券(06066.HK) +0.220 (+1.587%) 沽空 $2.35千万; 比率 8.176% │26%恒瑞医药(01276.HK) +2.950 (+3.841%) 沽空 $1.03亿; 比率 24.298% │25%海丰国际(01308.HK) +0.820 (+2.980%) 沽空 $1.63千万; 比率 14.767% │23%药明康德(02359.HK) +4.500 (+4.072%) 沽空 $2.49亿; 比率 17.045% │22%(wl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-10-27 16:25。)